A Phase 1 interventional study of Rotigotine (Test product PR 2.3.1) and Rotigotine (Reference product PR 2.1.1) in Parkinson's Disease, sponsored by UCB BIOSCIENCES GmbH. Completed at 11 sites in Germany. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2015-11-02.
Sponsored by UCB BIOSCIENCES GmbH (part of UCB S.A.) · Phase 1, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 44 studies testing rotigotine in Parkinson Disease — 1 open to participants now, 1 under way, none of them phase 3. rotigotine · Parkinson Disease.
Among the 44 studies testing rotigotine in Parkinson Disease, this one is the 31st largest by enrollment of the 42 interventional ones that give a count, is the only one that started in 2014, is one of 6 in phase 1, and was the 37th registered.
4,578 studies on the registry are indexed under Parkinson Disease; 1,085 are open to participants now.
Browse Parkinson Disease studies →1 of the 44 studies testing rotigotine in Parkinson Disease is open now. Recruiting first, the newest first:
Eva Pharma
Ages 30+
rotigotine: first FDA approval 2007 (NEUPRO), first EMA approval 2006. What it is approved for, and how studies give it, is on its page →
Of the 748 Parkinson Disease studies recruiting now, 311 (42%) set no upper age limit and 127 (17%) stop at 75 or younger; 64 take children under 18; 189 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
44 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 6 · Phase 2 9 · Phase 3 22 · Phase 4 8
First in 1999; this study’s year is marked. 1 started in 2014.
This study's enrollment of 57 is above the median of 40 across 3,357 interventional studies indexed under Parkinson Disease.
Median enrollment 123 across the 42 interventional studies. Of the 41 that completed or were terminated, 30 (73%) have results posted.
This tab as a report to print or save as PDF → With an account.
38 of 44 have an industry lead sponsor. The 10 most frequent:
This study is registered under UCB BIOSCIENCES GmbH, one of the names counted as UCB S.A.. Under that name alone:
UCB BIOSCIENCES GmbH is the lead sponsor of 21 studies on the registry; none are open to participants now.
44 studies in Parkinson Disease by UCB S.A.: none open now, none under way, none of them phase 3. Of 44 finished, 29 (66%) have results posted.
Among the 44 studies in Parkinson Disease by UCB S.A., this one is the 27th largest by enrollment of the 34 interventional ones that give a count, is one of 2 that started in 2014, is one of 7 in phase 1, and was the 37th registered.
UCB S.A.’s Parkinson Disease studies by the year they started, since 2002.
None of the studies under way reaches primary completion within a year.
Among the 44 studies testing rotigotine in Parkinson Disease, from their registry updates:
Nothing recorded among them since 2026-09-25.
Among UCB S.A.’s 44 in Parkinson Disease:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
The primary objective of the study is to compare the adhesiveness of 2 different patch formulations of Rotigotine using the largest patch size of 40 cm\^2, under the assumption that both patch formulations show similar adhesiveness properties.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Hypersensitivity
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
4 day treatment (Treatment A: Rotigotine transdermal patch 8 mg/24 hours, test product PR 2.3.1 followed by Treatment B: Rotigotine transdermal patch 8 mg/24 hours reference product PR 2.1.1)
Drug: Rotigotine (Test product PR 2.3.1) · Drug: Rotigotine (Reference product PR 2.1.1)
4 day treatment (Treatment B: Rotigotine transdermal patch 8 mg/24 hours reference product PR 2.1.1 followed by Treatment A: Rotigotine transdermal patch 8 mg/24 hours, test product PR 2.3.1)
Drug: Rotigotine (Test product PR 2.3.1) · Drug: Rotigotine (Reference product PR 2.1.1)
* Pharmaceutical form: Transdermal patch * Concentration: 8 mg/24 hours * Route of administration: Transdermal
* Pharmaceutical form: Transdermal patch * Concentration: 8 mg/24 hours * Route of administration: Transdermal
Also known as: Neupro
Change in Average Adhesiveness Score of 2 Days of 24 Hours Patch Application as Rated by the Investigator (or Designee) Assessed According to the EMA Draft Guideline
The assessment was performed according to the adhesion score adapted from the EMA draft guideline on quality of transdermal patches (EMA/CHMMP/QWP/911254/2011, 2012). * 0 = \> 95 - 100 % of the patch area adheres * 1 = \> 90 - 95 % of the patch adheres * 2 = \> 85 - 90 % of the patch adheres * 3 = \> 80 - 85 % of the patch adheres * 4 = \> 75 - 80 % of the patch adheres * 5 = \> 70 - 75 % of the patch adheres * 6 = ≥ 50 - 70 % of the patch adheres * 7 = \< 50 % of the patch adheres * 8 = Patch completely detached The recorded scores 6, 7, and 8 were combined in order to create a cumulative group "less than or equal to 70 % adhered or patch detachment" which was regarded as significant patch adhesion failure in the draft EMA guideline. The average of patches 1 and 2 is presented by Treatment Arm below.
Time frame: Patch adhesiveness was measured after 24 hours (±1 hour) after previous patch application on Day 2, 3, 4 and 5
Patch Adhesiveness Per Day as Rated by the Investigator or Designee 24 Hours After Patch Application According to the EMA Draft Guideline for Patch 1
The assessment was performed according to the adhesion score adapted from the EMA draft guideline on quality of transdermal patches (EMA/CHMMP/QWP/911254/2011, 2012). * 0 = \>95 - 100 % of the patch area adheres * 1 = \>90 - 95 % of the patch adheres * 2 = \>85 - 90 % of the patch adheres * 3 = \>80 - 85 % of the patch adheres * 4 = \>75 - 80 % of the patch adheres * 5 = \>70 - 75 % of the patch adheres * 6 = ≥50 - 70 % of the patch adheres * 7 = \<50 % of the patch adheres * 8 = Patch completely detached The recorded scores 6, 7, and 8 were combined in order to create a cumulative group "less than or equal to 70 % adhered or patch detachment" which was regarded as significant patch adhesion failure in the draft EMA guideline.
Time frame: Patch adhesiveness was measured 24 hours (±1 hour) after previous patch application on Day 2 and 4
Patch Adhesiveness Per Day as Rated by the Investigator 24 Hours After Patch Application According to the EMA Draft Guideline for Patch 2
The assessment was performed according to the adhesion score adapted from the EMA draft guideline on quality of transdermal patches (EMA/CHMMP/QWP/911254/2011, 2012). * 0 = \>95 - 100 % of the patch area adheres * 1 = \>90 - 95 % of the patch adheres * 2 = \>85 - 90 % of the patch adheres * 3 = \>80 - 85 % of the patch adheres * 4 = \>75 - 80 % of the patch adheres * 5 = \>70 - 75 % of the patch adheres * 6 = ≥50 - 70 % of the patch adheres * 7 = \<50 % of the patch adheres * 8 = Patch completely detached The recorded scores 6, 7, and 8 were combined in order to create a cumulative group "less than or equal to 70 % adhered or patch detachment" which was regarded as significant patch adhesion failure in the draft EMA guideline.
Time frame: Patch adhesiveness was measured 24 hours (±1 hour) after previous patch application on Day 3 and 5
Patch Adhesiveness Per Day as Rated by the Investigator 24 Hours After Patch Application According to the FDA/Center for Drug Evaluation and Research (CDER) Score for Patch 1
The assessment was performed according to the adhesion score adapted from the EMA draft guideline on quality of transdermal patches . Afterwards, EMA scores were translated into FDA/CDER scores: * 0 (\>95-100% of patch adheres) \>\> 0 (FDA/CDER) * 1 (\>90-95% of patch adheres) \>\> 0 (FDA/CDER) * 2 (\>85-90% of patch adheres) \>\> 1 (FDA/CDER) * 3 (\>80-85% of patch adheres) \>\> 1 (FDA/CDER) * 4 ( \>75-80% of patch adheres) \>\> 1 (FDA/CDER) * 5 (\>70-75% of patch adheres) \>\> 2 (FDA/CDER) * 6 (≥50-70% of patch adheres) \>\> 2 (FDA/CDER) * 7 (\<50 % of patch adheres) \>\> 3 (FDA/CDER) * 8 (Patch completely detached) \>\> 4 (FDA/CDER) Due to a slight mismatch of limits between FDA scores 0 and 1 as compared to EMA scores 1 and 2, the theoretical value of exactly 90 % of adh. fell into score 1 with the FDA scoring. A similar limit mismatch occured at exactly 75 %. These mismatches may have resulted in a slightly worse estimation of the adh. with the FDA score as compared to previous adh. studies.
Time frame: Patch adhesiveness was measured 24 hours (±1 hour) after previous patch application on Day 2 and 4
Patch Adhesiveness Per Day as Rated by the Investigator 24 Hours After Patch Application According to the FDA/Center for Drug Evaluation and Research (CDER) Score for Patch 2
The assessment was performed according to the adhesion score adapted from the EMA draft guideline on quality of transdermal patches . Afterwards, EMA scores were translated into FDA/CDER scores: * 0 (\>95-100% of patch adheres) \>\> 0 (FDA/CDER) * 1 (\>90-95% of patch adheres) \>\> 0 (FDA/CDER) * 2 (\>85-90% of patch adheres) \>\> 1 (FDA/CDER) * 3 (\>80-85% of patch adheres) \>\> 1 (FDA/CDER) * 4 ( \>75-80% of patch adheres) \>\> 1 (FDA/CDER) * 5 (\>70-75% of patch adheres) \>\> 2 (FDA/CDER) * 6 (≥50-70% of patch adheres) \>\> 2 (FDA/CDER) * 7 (\<50 % of patch adheres) \>\> 3 (FDA/CDER) * 8 (Patch completely detached) \>\> 4 (FDA/CDER) Due to a slight mismatch of limits between FDA scores 0 and 1 as compared to EMA scores 1 and 2, the theoretical value of exactly 90 % of adh. fell into score 1 with the FDA scoring. A similar limit mismatch occured at exactly 75 %. These mismatches may have resulted in a slightly worse estimation of the adh. with the FDA score as compared to previous adh. studies.
Time frame: Patch adhesiveness was measured 24 hours (±1 hour) after previous patch application on Day 3 and 5
Patch Adhesiveness Per Day as Rated by the Subject 24 Hours After Patch Application for Patch 1
The subject assessed the patch adhesiveness by using the following score: * 0 = Satisfied with adhesiveness * 1 = Moderately satisfied with adhesiveness * 2 = Moderately unsatisfied with adhesiveness * 3 = Unsatisfied with adhesiveness
Time frame: Patch adhesiveness was measured 24 hours (±1 hour) after previous patch application on Day 2 and 4
Patch Adhesiveness Per Day as Rated by the Subject 24 Hours After Patch Application for Patch 2
The subject assessed the patch adhesiveness by using the following score: * 0 = Satisfied with adhesiveness * 1 = Moderately satisfied with adhesiveness * 2 = Moderately unsatisfied with adhesiveness * 3 = Unsatisfied with adhesiveness
Time frame: Patch adhesiveness was measured 24 hours (±1 hour) after previous patch application on Day 3 and 5
Change in Average Patch Adhesiveness Score of 2 Days of 24 Hour Patch Application as Rated by the Investigator (or Designee), Assessed According to the FDA/Center for Drug Evaluation and Research (CDER) Score
The assessment was performed according to the adhesion score adapted from the EMA draft guideline on quality of transdermal patches . Afterwards, EMA scores were translated into FDA/CDER scores: * 0 (\>95-100% of patch adheres) \>\> 0 (FDA/CDER) * 1 (\>90-95% of patch adheres) \>\> 0 (FDA/CDER) * 2 (\>85-90% of patch adheres) \>\> 1 (FDA/CDER) * 3 (\>80-85% of patch adheres) \>\> 1 (FDA/CDER) * 4 ( \>75-80% of patch adheres) \>\> 1 (FDA/CDER) * 5 (\>70-75% of patch adheres) \>\> 2 (FDA/CDER) * 6 (≥50-70% of patch adheres) \>\> 2 (FDA/CDER) * 7 (\<50 % of patch adheres) \>\> 3 (FDA/CDER) * 8 (Patch completely detached) \>\> 4 (FDA/CDER) Due to a slight mismatch of limits between FDA scores 0 and 1 as compared to EMA scores 1 and 2, the theoretical value of exactly 90 % of adh. fell into score 1 with the FDA scoring. A similar limit mismatch occured at exactly 75 %. These mismatches may have resulted in a slightly worse estimation of the adh. with the FDA score as compared to previous adh. studies.
Time frame: Patch adhesiveness was measured 24 hours (±1 hour) after previous patch application on Day 2, 3, 4 and 5
This study started to enroll subjects in September 2014 in Germany and concluded in December 2014.
| Milestone | Treatment Arm A-B | Treatment Arm B-A |
|---|---|---|
| Started | 29 | 28 |
| Completed | 29 | 27 |
| Not completed | 0 | 1 |
| Withdrew: Safety follow up could not take place | 0 | 1 |
The assessment was performed according to the adhesion score adapted from the EMA draft guideline on quality of transdermal patches (EMA/CHMMP/QWP/911254/2011, 2012). * 0 = \> 95 - 100 % of the patch area adheres * 1 = \> 90 - 95 % of the patch adheres * 2 = \> 85 - 90 % of the patch adheres * 3 = \> 80 - 85 % of the patch adheres * 4 = \> 75 - 80 % of the patch adheres * 5 = \> 70 - 75 % of the patch adheres * 6 = ≥ 50 - 70 % of the patch adheres * 7 = \< 50 % of the patch adheres * 8 = Patch completely detached The recorded scores 6, 7, and 8 were combined in order to create a cumulative group "less than or equal to 70 % adhered or patch detachment" which was regarded as significant patch adhesion failure in the draft EMA guideline. The average of patches 1 and 2 is presented by Treatment Arm below.
| units on a scale | Treatment A | Treatment B |
|---|---|---|
| Change in Average Adhesiveness Score of 2 Days of 24 Hours Patch Application as Rated by the Investigator (or Designee) Assessed According to the EMA Draft Guideline | 1.04 ± 1.33 | 2.15 ± 1.96 |
The assessment was performed according to the adhesion score adapted from the EMA draft guideline on quality of transdermal patches (EMA/CHMMP/QWP/911254/2011, 2012). * 0 = \>95 - 100 % of the patch area adheres * 1 = \>90 - 95 % of the patch adheres * 2 = \>85 - 90 % of the patch adheres * 3 = \>80 - 85 % of the patch adheres * 4 = \>75 - 80 % of the patch adheres * 5 = \>70 - 75 % of the patch adheres * 6 = ≥50 - 70 % of the patch adheres * 7 = \<50 % of the patch adheres * 8 = Patch completely detached The recorded scores 6, 7, and 8 were combined in order to create a cumulative group "less than or equal to 70 % adhered or patch detachment" which was regarded as significant patch adhesion failure in the draft EMA guideline.
| percentage of patches | Treatment A | Treatment B |
|---|---|---|
| > 95 % | 65.4 | 46.2 |
| > 90 % - 95 % | 11.5 | 17.3 |
| > 85 % - 90 % | 7.7 | 5.8 |
| > 80 % - 85 % | 3.8 | 9.6 |
| > 75 % - 80 % | 3.8 | 1.9 |
| > 70 % - 75 % | 0 | 1.9 |
| <= 70 % | 7.7 | 17.3 |
| Missing | 0 | 0 |
The assessment was performed according to the adhesion score adapted from the EMA draft guideline on quality of transdermal patches (EMA/CHMMP/QWP/911254/2011, 2012). * 0 = \>95 - 100 % of the patch area adheres * 1 = \>90 - 95 % of the patch adheres * 2 = \>85 - 90 % of the patch adheres * 3 = \>80 - 85 % of the patch adheres * 4 = \>75 - 80 % of the patch adheres * 5 = \>70 - 75 % of the patch adheres * 6 = ≥50 - 70 % of the patch adheres * 7 = \<50 % of the patch adheres * 8 = Patch completely detached The recorded scores 6, 7, and 8 were combined in order to create a cumulative group "less than or equal to 70 % adhered or patch detachment" which was regarded as significant patch adhesion failure in the draft EMA guideline.
| percentage of patches | Treatment A | Treatment B |
|---|---|---|
| > 95 % | 71.2 | 36.5 |
| > 90 % - 95 % | 5.8 | 7.7 |
| > 85 % - 90 % | 3.8 | 9.6 |
| > 80 % - 85 % | 3.8 | 9.6 |
| > 75 % - 80 % | 3.8 | 9.6 |
| > 70 % - 75 % | 1.9 | 3.8 |
| <= 70 % | 9.6 | 23.1 |
| Missing | 0 | 0 |
The assessment was performed according to the adhesion score adapted from the EMA draft guideline on quality of transdermal patches . Afterwards, EMA scores were translated into FDA/CDER scores: * 0 (\>95-100% of patch adheres) \>\> 0 (FDA/CDER) * 1 (\>90-95% of patch adheres) \>\> 0 (FDA/CDER) * 2 (\>85-90% of patch adheres) \>\> 1 (FDA/CDER) * 3 (\>80-85% of patch adheres) \>\> 1 (FDA/CDER) * 4 ( \>75-80% of patch adheres) \>\> 1 (FDA/CDER) * 5 (\>70-75% of patch adheres) \>\> 2 (FDA/CDER) * 6 (≥50-70% of patch adheres) \>\> 2 (FDA/CDER) * 7 (\<50 % of patch adheres) \>\> 3 (FDA/CDER) * 8 (Patch completely detached) \>\> 4 (FDA/CDER) Due to a slight mismatch of limits between FDA scores 0 and 1 as compared to EMA scores 1 and 2, the theoretical value of exactly 90 % of adh. fell into score 1 with the FDA scoring. A similar limit mismatch occured at exactly 75 %. These mismatches may have resulted in a slightly worse estimation of the adh. with the FDA score as compared to previous adh. studies.
| percentage of patches | Treatment A | Treatment B |
|---|---|---|
| >= 90 % | 76.9 | 63.5 |
| 75 % -< 90 % | 15.4 | 17.3 |
| 50 % -< 75 % | 1.9 | 11.5 |
| < 50 % | 3.8 | 0 |
| Detached | 1.9 | 7.7 |
| Missing | 0 | 0 |
The assessment was performed according to the adhesion score adapted from the EMA draft guideline on quality of transdermal patches . Afterwards, EMA scores were translated into FDA/CDER scores: * 0 (\>95-100% of patch adheres) \>\> 0 (FDA/CDER) * 1 (\>90-95% of patch adheres) \>\> 0 (FDA/CDER) * 2 (\>85-90% of patch adheres) \>\> 1 (FDA/CDER) * 3 (\>80-85% of patch adheres) \>\> 1 (FDA/CDER) * 4 ( \>75-80% of patch adheres) \>\> 1 (FDA/CDER) * 5 (\>70-75% of patch adheres) \>\> 2 (FDA/CDER) * 6 (≥50-70% of patch adheres) \>\> 2 (FDA/CDER) * 7 (\<50 % of patch adheres) \>\> 3 (FDA/CDER) * 8 (Patch completely detached) \>\> 4 (FDA/CDER) Due to a slight mismatch of limits between FDA scores 0 and 1 as compared to EMA scores 1 and 2, the theoretical value of exactly 90 % of adh. fell into score 1 with the FDA scoring. A similar limit mismatch occured at exactly 75 %. These mismatches may have resulted in a slightly worse estimation of the adh. with the FDA score as compared to previous adh. studies.
| percentage of patches | Treatment A | Treatment B |
|---|---|---|
| >= 90 % | 76.9 | 44.2 |
| 75 % -< 90 % | 11.5 | 28.8 |
| 50 % -< 75 % | 3.8 | 17.3 |
| < 50 % | 7.7 | 3.8 |
| Detached | 0 | 5.8 |
| Missing | 0 | 0 |
The subject assessed the patch adhesiveness by using the following score: * 0 = Satisfied with adhesiveness * 1 = Moderately satisfied with adhesiveness * 2 = Moderately unsatisfied with adhesiveness * 3 = Unsatisfied with adhesiveness
| percentage of patches | Treatment A | Treatment B |
|---|---|---|
| 0 = Satisfied with adhesiveness | 75.0 | 65.4 |
| 1 = Moderately satisfied with adhesiveness | 17.3 | 13.5 |
| 2 = Moderately unsatisfied with adhesiveness | 3.8 | 9.6 |
| 3 = Unsatisfied with adhesiveness | 3.8 | 11.5 |
The subject assessed the patch adhesiveness by using the following score: * 0 = Satisfied with adhesiveness * 1 = Moderately satisfied with adhesiveness * 2 = Moderately unsatisfied with adhesiveness * 3 = Unsatisfied with adhesiveness
| percentage of patches | Treatment A | Treatment B |
|---|---|---|
| 0 = Satisfied with adhesiveness | 73.1 | 59.6 |
| 1 = Moderately satisfied with adhesiveness | 15.4 | 26.9 |
| 2 = Moderately unsatisfied with adhesiveness | 9.6 | 5.8 |
| 3 = Unsatisfied with adhesiveness | 1.9 | 7.7 |
The assessment was performed according to the adhesion score adapted from the EMA draft guideline on quality of transdermal patches . Afterwards, EMA scores were translated into FDA/CDER scores: * 0 (\>95-100% of patch adheres) \>\> 0 (FDA/CDER) * 1 (\>90-95% of patch adheres) \>\> 0 (FDA/CDER) * 2 (\>85-90% of patch adheres) \>\> 1 (FDA/CDER) * 3 (\>80-85% of patch adheres) \>\> 1 (FDA/CDER) * 4 ( \>75-80% of patch adheres) \>\> 1 (FDA/CDER) * 5 (\>70-75% of patch adheres) \>\> 2 (FDA/CDER) * 6 (≥50-70% of patch adheres) \>\> 2 (FDA/CDER) * 7 (\<50 % of patch adheres) \>\> 3 (FDA/CDER) * 8 (Patch completely detached) \>\> 4 (FDA/CDER) Due to a slight mismatch of limits between FDA scores 0 and 1 as compared to EMA scores 1 and 2, the theoretical value of exactly 90 % of adh. fell into score 1 with the FDA scoring. A similar limit mismatch occured at exactly 75 %. These mismatches may have resulted in a slightly worse estimation of the adh. with the FDA score as compared to previous adh. studies.
| units on a scale | Treatment A | Treatment B |
|---|---|---|
| Change in Average Patch Adhesiveness Score of 2 Days of 24 Hour Patch Application as Rated by the Investigator (or Designee), Assessed According to the FDA/Center for Drug Evaluation and Research (CDER) Score | 0.40 ± 0.60 | 0.85 ± 1.03 |
Collected over Treatment-emergent Adverse Events were collected from Visit 2 (Day 1) up to the Safety Follow-up Visit (Day 12).. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Treatment A | — | 0/57 (0%) | 7/57 (12.3%) |
| Treatment B | — | 0/57 (0%) | 1/57 (1.8%) |
| Event | Treatment A | Treatment B |
|---|---|---|
| ErythemaSkin and subcutaneous tissue disorders | 7/57 | 1/57 |
Baseline characteristics refer to the Safety Set, consisting of all randomized subjects who entered the study and received at least 1 dose of study medication.
| Age, Categorical(Participants) | Treatment Arm A-B | Treatment Arm B-A | Total Title |
|---|---|---|---|
| <=18 years | 0 | 0 | 0 |
| Between 18 and 65 years | 11 | 8 | 19 |
| >=65 years | 18 | 20 | 38 |
| Age, Continuous(years) | Treatment Arm A-B | Treatment Arm B-A | Total Title |
|---|---|---|---|
| Mean | 67.3 ± 10.9 | 69.6 ± 9.5 | 68.4 ± 10.2 |
| Sex: Female, Male(Participants) | Treatment Arm A-B | Treatment Arm B-A | Total Title |
|---|---|---|---|
| Female | 4 | 9 | 13 |
| Male | 25 | 19 | 44 |
The record gives a start of Sep 2014, a primary completion of Nov 2014 and a completion of Dec 2014. It does not say whether these dates are actual or estimated.
Results were first posted in Nov 2015, 1 year after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Oct 2015. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Rotigotine